Multiple action mechanism and in vivo antimicrobial efficacy of antimicrobial peptide Jelleine‐I,Journal of Peptide Science

当前位置： X-MOL 学术 › J. Pept. Sci. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Multiple action mechanism and in vivo antimicrobial efficacy of antimicrobial peptide Jelleine‐I
Journal of Peptide Science ( IF 1.8 ) Pub Date : 2020-12-06 , DOI: 10.1002/psc.3294
Fengjing Jia ₁ , Jiayi Wang ₁ , Lishi Zhang ₁ , Jingjing Zhou ₁ , Yuhang He ₁ , Yaqi Lu ₁ , Kexin Liu ₂ , Wenjin Yan ₁ , Kairong Wang ₁

Affiliation

With the extensive use of antibiotics in medicine, agriculture and food chemistry, the emergence of multi‐drug resistant bacteria become more and more frequent and posed great threats to human health and life. So novel antimicrobial agents were urgently needed to defend the resistant bacteria. Jelleine‐I was a small antimicrobial peptide (AMP) with eight amino acids in its sequence. It was believed to be an ideal template for developing antimicrobial agents. In the present study, the possible action mode against both gram‐negative bacteria and gram‐positive bacteria and in vivo antimicrobial activity was explored. Our results showed that Jelleine‐I exhibits its antimicrobial activity mainly by disrupting the integrity of the cell membrane, which would not be affected by the conventional resistant mechanism. It also aims at some intracellular targets such as genomic DNA to inhibit the growth of microbes. In addition, the result of in vivo antimicrobial activity experiment showed that Jelleine‐I performed a good therapeutic effect toward the mice with Escherichia coli infected peritonitis. Notably, Jelleine‐I has negligible cytotoxicity toward the tested mammalian cells, indicating excellent cell selectivity between prokaryotic cells and eurkayotic cells. In summary, our results showed that Jelleine‐I would be a potential candidate to be developed as a novel antimicrobial agent.

中文翻译：

抗菌肽Jelleine-I的多重作用机制及体内抗菌功效

随着抗生素在医药、农业和食品化学中的广泛使用，多重耐药菌的出现越来越频繁，对人类健康和生命构成了极大威胁。因此，迫切需要新型抗菌剂来保护耐药细菌。Jelleine-I 是一种小的抗菌肽 (AMP)，其序列中有 8 个氨基酸。它被认为是开发抗微生物剂的理想模板。在本研究中，探讨了对革兰氏阴性菌和革兰氏阳性菌的可能作用模式以及体内抗菌活性。我们的结果表明，Jelleine-I 主要通过破坏细胞膜的完整性来表现出其抗菌活性，而不受传统耐药机制的影响。它还针对一些细胞内靶标，例如基因组 DNA，以抑制微生物的生长。此外，体内抗菌活性实验结果表明，Jelleine-I对小鼠具有良好的治疗效果。大肠杆菌感染腹膜炎。值得注意的是，Jelleine-I 对受试哺乳动物细胞的细胞毒性可以忽略不计，表明原核细胞和真核细胞之间具有出色的细胞选择性。总而言之，我们的结果表明 Jelleine-I 将成为一种潜在的候选物，可以开发为一种新型抗菌剂。

更新日期：2021-01-28

点击分享查看原文

点击收藏

阅读更多本刊最新论文本刊介绍/投稿指南11